Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3)

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  MacMillan, Carolyn J ^a   Doucette, Carolyn D ^a   Warford, Jordan ^a   Furlong, Suzanne J ^a   Hoskin, David W ^a   Easton, Alexander S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; MONOCLONAL ANTIBODY B20 4.1.1; RECOMBINANT ANGIOSTATIN KRINGLE DOMAIN 1 3; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOSTATIN; VASCULOTROPIN A;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SPINAL CORD; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; CAPILLARY PERMEABILITY; COMPLICATION; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; T LYMPHOCYTE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; CAPILLARY PERMEABILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; MICE; NEOVASCULARIZATION, PATHOLOGIC; SPINAL CORD; T-LYMPHOCYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896375197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089770     Document Type: Article

References (33)

1. Ludwin SK, Henry JM, McFarland HF (2001) Vascular proliferation and angiogenesis in MS: clinical and pathogenic implications. J Neuropathol Exp Neurol 60: 505.
2. Holley JE, Newcombe J, Whatmore JL, Gutowski NJ (2010) Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett 470: 65-70.
3. Kirk SL, Karlik SJ (2003) VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 21: 353-363. (Pubitemid 37420080)
4. Roscoe WA, Welsh ME, Carter DE, Karlik SJ (2009) VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. J Neuroimmunol 209: 6-15.
5. Seabrook TJ, Littlewood-Evans A, Brinkmann V, Pollinger B, Schnell C, et al. (2010) Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. J Neuroinflammation 7: 95.
6. MacMillan CJ, Starkey RJ, Easton AS (2011) Angiogenesis is regulated by angiopoietins during experimental autoimmune encephalomyelitis and is indirectly related to vascular permeability. J Neuropathol Exp Neurol 70: 1107-1123.
7. MacMillan CJ, Furlong SJ, Doucette CD, Chen P-L, Hoskin DW, et al. (2012) Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T cell responses. J Neuropathol Exp Neurol 71: 983-999.
8. Yu L, Wu X, Cheng Z, Lee CV, Le Couter J, et al. (2008) Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49: 522-527.
9. El-behi M, Rostami A, Ciric B (2010) Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 5: 189-197.
10. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, et al. (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281: 951-961.
11. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, et al. (1996) Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271: 29461-29467. (Pubitemid 26382666)
12. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, et al. (1999) Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811-2816. (Pubitemid 29148800)
13. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L (2001) Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152: 1247-1254. (Pubitemid 34280181)
14. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, et al. (2001) Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 98: 6656-6661. (Pubitemid 32538272)
15. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, et al. (1998) Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 95: 6367-6372. (Pubitemid 28249018)
16. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, et al. (1998) Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 95: 5579-5583. (Pubitemid 28224137)
17. Lu H, Dhanabal M, Volk R, Waterman MJ, Ramchandran R, et al. (1999) Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 258: 668-673. (Pubitemid 29290327)
18. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, et al. (1998) Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92: 4730-4741. (Pubitemid 29005875)
19. MacDonald NJ, Murad AC, Fogler WE, Lu Y, et al. (1999) The tumor-suppressing ability of angiostatin protein resides within kringles 1-3. Biochem Biophys Res Commun 264: 469-477. (Pubitemid 29516110)
20. Gauden V, Hu DE, Kurokawa T, Sarker MH, Fraser PA (2007) Novel technique for estimating cerebrovascular permeability demonstrates capsazepine protection following ischemia-reperfusion. Microcirculation 14: 767-778. (Pubitemid 350131386)
21. Joice SL, Mydeen F. Couraud P-O, Weksler B, Romero IA, et al. (2009) Modulation of blood-brain barrier permeability by neutrophils: in vitro and in vivo studies. Brain Res 1298: 13-23.
22. Rapoport SI (1978) A mathematical model for vasogenic brain edema. J Theor Biol 74: 439-467.
23. Schlageter KE, Molnar P, Lapin GD, Groothuis DR (1999) Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 58: 312-328. (Pubitemid 29531878)
24. Easton AS, Sarker MH, Fraser PA (1997) Two components of blood-brain barrier disruption in the rat. J Physiol 503: 613-623. (Pubitemid 27496672)
25. Cao Y (2004) Antiangiogenic cancer therapy. Semin Cancer Biol 14: 139-145.
26. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ (2002) Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61: 914-925.
27. Tham E, Gielen AW, Khademi M, Martin C, Piehl F (2006) Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand J Immunol 64: 609-622. (Pubitemid 44704310)
28. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400. (Pubitemid 38618122)
29. Weller RO, Djuanda E, Yow H, Carare RO (2009) Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117: 1-14.
30. des Guetz G, Uzzan B, Chouahnia K, Morere JF (2011) Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol 6: 197-202.
31. Young RJ, Reed MW (2012) Anti-angiogenic therapy: concept to clinic. Microcirculation 19: 115-125.
32. Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, et al. (2003) Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 9: 4025-4033. (Pubitemid 37204017)
33. Kurup A, Lin CW, Murry DJ, Dobrolecki L, Estes D, et al. (2006) Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 17: 97-103. (Pubitemid 43033847)